Literature DB >> 36169704

[Rheumatology centers according to the regulations of the Federal Joint Committee].

Heinz-Jürgen Lakomek1, Wolfgang Fiori2.   

Abstract

With the Nursing Staff Strengthening Act (Pflegepersonal-Stärkungs-Gesetz), the legislator delegated the specification of the special tasks of centers and focal points to the Federal Joint Committee (G-BA). Due to extensive preliminary work it was already possible to agree on quality requirements and special tasks for rheumatology centers and centers for pediatric and adolescent rheumatology in the first version of the G‑BA regulations. Since publication in the Federal Gazette (Bundesanzeiger) on 12 March 2020, rheumatology centers have been able to negotiate surcharges for their special tasks if they have been designated accordingly by the state authorities responsible for hospital planning. So far, 14 rheumatological centers have been designated. Many patients continue to be treated in healthcare structures that are not specialized in acute inpatient rheumatological care. In addition to the additional remuneration, the designation as a rheumatology center can also contribute to patients becoming even more aware of the healthcare structures that are specialized for them. Acute inpatient rheumatology has several specializations. Some clinics have specialized in the multimodal treatment of chronic rheumatism patients and have gained a high level of expertise in this field. Many of these highly specialized clinics have so far been denied recognition as a center because the regulations of the G‑BA require the provision of further specialist departments at the same location. While for a large number of medical specializations the establishment at a maximum care hospital is likely to make sense, the specialist clinics focusing on the multimodal treatment of chronic rheumatism patients offer the possibility of strengthening rural areas.
© 2022. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.

Entities:  

Keywords:  Association of Rheumatological Acute Clinics (VRA); Centers for pediatric and adolescent rheumatology; Continuous outcome benchmarking in rheumatological acute treatment (KOBRA); Federal Joint Committee (G-BA); Structural requirements

Year:  2022        PMID: 36169704     DOI: 10.1007/s00393-022-01270-w

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.530


  6 in total

1.  [Aging with rheumatic diseases].

Authors:  E Märker-Hermann; H-J Lakomek
Journal:  Z Rheumatol       Date:  2018-06       Impact factor: 1.372

2.  [Polymyalgia rheumatica in 18-fluorodeoxyglucose-positron-emission-tomography/computed tomography : Improvement in diagnostic accuracy and differentiation from rheumatoid arthritis].

Authors:  F Witte; H-J Lakomek; J Holzinger; W-D Reinbold
Journal:  Z Rheumatol       Date:  2021-12-01       Impact factor: 1.372

3.  [Therapeutic effects of complex multimodal rheumatologic treatment in the Rheumatology Center, Rhineland-Palatinate].

Authors:  K Triantafyllias; C Sauer; A Schwarting
Journal:  Z Rheumatol       Date:  2022-05-09       Impact factor: 1.530

Review 4.  [Special medical outpatient care-3.5 years of outpatient specialist care in rheumatology : An inventory].

Authors:  Anna Sollacher; Sonja Froschauer; Laura Bredow; Silke Zinke
Journal:  Z Rheumatol       Date:  2022-04-08       Impact factor: 1.530

5.  [Quality in acute inpatient rheumatology 2021 : Current aspects of the KOBRA quality label of the Association of Rheumatological Acute Care Clinics].

Authors:  H-J Lakomek; M Rudwaleit; A Hentschel; B Broge; J Abrolat; F Bessler; B Hellmich; A Klemann; A Krause; M Klass; J Strunk; W Fiori; N Roeder; J Braun
Journal:  Z Rheumatol       Date:  2021-05-17       Impact factor: 1.372

Review 6.  [Rheumatologic inpatient treatment-more than a complex treatment : Data reflecting services and structures].

Authors:  Wolfgang Fiori; Heinz-Jürgen Lakomek; Johannes Strunk; Ansgar Klemann
Journal:  Z Rheumatol       Date:  2022-04-01       Impact factor: 1.530

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.